907. Outcomes Research: Plasma Cell Disorders: Poster II

Outcomes of urgent inpatient chemotherapy for relapsed refractory multiple myeloma in the modern era

Cytomegalovirus reactivation in teclistamab treated multiple myeloma patients Clinical outcomes and risk factors

Bridging the rural gap Real world teclistamab outcomes from the u S midwest myeloma network

Real world incidence and management of non icans neurologic events following ciltacabtagene autoleucel in multiple myeloma

Real world analysis of infections after bispecific antibodies targeting anti B cell maturation antigen BCMA and protective impact of intravenous immunoglobulin IVIG in patients with multiple myeloma

Trends and disparities in multiple myeloma mortality in the United States A 25 year analysis from 1999 to 2023

Real world outcomes with CAR T therapy in relapsed refractory multiple myeloma and severe renal failure A propensity matched multi center retrospective Study using trinetx database

Outcomes of CAR T therapy in HIV positive multiple myeloma patients A retrospective database analysis

Artificial intelligence machine learning based risk prediction model guiding individualized interventions to improve outcomes for patients with multiple myeloma

Real world efficacy and safety of elranatamab a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma An international myeloma working group immunotherapy database analysis

National cross sectional Study to explore current state of patient awareness of multiple myeloma MM disease basics and its management Identifying gaps and associations

Non response to bridging therapy prior to CAR T is associated with increased toxicity and adverse outcomes in Relapsed Refractory multiple myeloma RRMM

Real world RW outcomes of newly diagnosed multiple myeloma NDMM patients pts treated with front line daratumumab dara bortezomib bor lenalidomide len and dexamethasone dex DVRd

Outcomes of multiple myeloma MM patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

Real world disease burden and treatment patterns among triple class–exposed patients with relapsed refractory multiple myeloma and extramedullary disease in the US A retrospective analysis using Flatiron Health electronic medical records

Survival outcomes of multiple myeloma patients previously exposed to BCMA targeted therapies in the honeur european network

B cell kinetics on next generation sequencing after CAR T cell therapy in multiple myeloma

Supportive care alone is effective for managing low grade CRS in multiple myeloma patients treated with bispecific antibodies

Risk factors and prevalence of monoclonal gammopathy of undetermined significance MGUS by duffy genotype

Bi specific T cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed Refractory multiple myeloma Real world outcomes in an underserved urban population

Incidence of severe infections in patients with multiple myeloma treated with immunoglobulin replacement therapy

Safety results from REALiTAL A multi country observational retrospective study of talquetamab in patients with relapsed refractory multiple myeloma outside of clinical trials

Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude 4 Oncologist treatment preferences in lenalidomide refractory multiple myeloma

Impact of vitamin d deficiency on quality of life and clinical outcomes in patients with multiple myeloma

Understanding access and treatment challenges in multiple myeloma care

Lenalidomide LEN and anti CD38 monoclonal antibodies mAbs utilization in patients with newly diagnosed and relapsed refractory multiple myeloma MM in Germany Real world insights on epidemiology and clinical outcomes

Optimizing skeletal health An analysis of bone modifying agent prescription patterns and incidence of skeletal related events in multiple myeloma

Treatment patterns and real world effectiveness in patients with Relapsed Refractory multiple myeloma RRMM and lenalidomide exposure who received 1 to 3 prior lines of therapy

Shifting symptom profiles and accelerated diagnosis in AL amyloidosis Findings from ARC community surveys 2022–2024

Real world comparison of progression free and overall survival between idecabtagene vicleucel ide cel and teclistamab in triple class exposed relapsed refractory multiple myeloma

Real world outcomes in relapsed refractory multiple myeloma Retreatment versus no retreatment with an anti CD38 monoclonal antibody in the 2L and 3L in patients from the Flatiron Health database